Biofrontera Inc
BFRI1.050USD
+0.010+0.96%
Horarios del mercado （ET）Cotizaciones retrasadas 15 min
9.32MCap. mercado
PérdidaP/E TTM
Más Datos de Biofrontera Inc Compañía
Biofrontera Inc. is a biopharmaceutical company. The Company is focused on commercializing a portfolio of pharmaceutical products for the treatment of dermatological conditions with a focus on photodynamic therapy (PDT) and topical antibiotics. The Company's licensed products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. Its principal licensed product is Ameluz, which is a prescription drug for use in combination with the BF-RhodoLED lamp series, for photodynamic therapy. In the United States, the PDT treatment is used for the lesion-directed and field-directed treatment of actinic keratoses (AK) of mild-to-moderate severity on the face and scalp. Its second prescription drug licensed product in its portfolio is Xepi, which is a topical non-fluorinated quinolone that inhibits bacterial growth and used for the treatment of impetigo due to Staphylococcus aureus or Streptococcus pyogenes.
Información de la empresa
Símbolo de cotizaciónBFRI
Nombre de la empresaBiofrontera Inc
Fecha de salida a bolsaOct 14, 2021
Director ejecutivoProf. Dr. Hermann Luebbert, Ph.D.
Número de empleados92
Tipo de seguridadOrdinary Share
Fin del año fiscalOct 14
Dirección120 Presidential Way,
CiudadWOBURN
Bolsa de valoresNASDAQ Capital Market Consolidated
PaísUnited States of America
Código postal01801
Teléfono17812451325
Sitio Webhttps://www.biofrontera-us.com/
Símbolo de cotizaciónBFRI
Fecha de salida a bolsaOct 14, 2021
Director ejecutivoProf. Dr. Hermann Luebbert, Ph.D.
Ejecutivos de la empresa
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
15.21K
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Nombre
Nombre/Posición
Posición
Accionistas
Cambio
Prof. Dr. Hermann Luebbert, Ph.D.
Prof. Dr. Hermann Luebbert, Ph.D.
Chairman of the Board, Chief Executive Officer
Chairman of the Board, Chief Executive Officer
15.21K
--
Dr. Beth J. Hoffman, Ph.D.
Dr. Beth J. Hoffman, Ph.D.
Independent Director
Independent Director
--
--
Mr. Eugene Frederick (Fred) Leffler, III
Mr. Eugene Frederick (Fred) Leffler, III
Chief Financial Officer
Chief Financial Officer
--
--
Dr. Heikki Lanckriet, Ph.D.
Dr. Heikki Lanckriet, Ph.D.
Director
Director
--
--
Dr. John J. Borer, III
Dr. John J. Borer, III
Independent Director
Independent Director
--
--
Mr. Kevin D. Weber
Mr. Kevin D. Weber
Independent Director
Independent Director
--
--
Desglose de ingresos
FY2024
FY2023
FY2022
FY2021
Sin datos
Por regiónUSD
Nombre
Ganancia
Proporción
United States
37.32M
0.00%
Por negocio
Por región
Sin datos
Estadísticas de accionistas
Actualizado: sáb., 17 de may
Actualizado: sáb., 17 de may
Accionistas
Tipos de accionistas
Accionistas
Accionistas
Proporción
AIGH Capital Management, LLC.
9.68%
Rosalind Advisors, Inc.
6.82%
Hewlett Fund, L.P.
5.82%
Biofrontera AG
4.23%
Worth Venture Partners, LLC
3.96%
Other
69.48%
Accionistas
Accionistas
Proporción
AIGH Capital Management, LLC.
9.68%
Rosalind Advisors, Inc.
6.82%
Hewlett Fund, L.P.
5.82%
Biofrontera AG
4.23%
Worth Venture Partners, LLC
3.96%
Other
69.48%
Tipos de accionistas
Accionistas
Proporción
Hedge Fund
10.43%
Private Equity
10.30%
Corporation
10.06%
Investment Advisor/Hedge Fund
4.39%
Individual Investor
3.41%
Investment Advisor
0.82%
Research Firm
0.20%
Other
60.40%
Participación institucional
Actualizado: mar., 1 de jul
Actualizado: mar., 1 de jul
Periodo del informe
Número de instituciones
Acciones mantenidas
Proporción
Cambio
2025Q2
43
3.55M
37.60%
-1.41M
2025Q1
47
3.28M
35.88%
-1.71M
2024Q4
48
3.72M
54.29%
+158.24K
2024Q3
43
3.76M
68.24%
+377.12K
2024Q2
45
3.39M
76.90%
-69.63K
2024Q1
45
3.44M
88.71%
+1.56M
2023Q4
40
853.94K
58.17%
+32.52K
2023Q3
43
649.68K
47.81%
-61.68K
2023Q2
41
673.17K
109.72%
-35.12K
2023Q1
40
667.34K
54.59%
-30.23K
Ver más
Actividad de los accionistas
Nombre
Acciones mantenidas
Proporción
Cambio
Cambio %
Fecha
AIGH Capital Management, LLC.
914.21K
9.68%
+556.50K
+155.57%
Apr 22, 2025
Rosalind Advisors, Inc.
644.39K
6.82%
--
--
Apr 22, 2025
Hewlett Fund, L.P.
550.22K
5.82%
-97.23K
-15.02%
Apr 22, 2025
Biofrontera AG
400.00K
4.23%
--
--
Dec 20, 2024
Worth Venture Partners, LLC
374.44K
3.96%
-70.34K
-15.82%
Mar 31, 2025
Lytton (Laurence W)
306.70K
3.25%
-228.98K
-42.75%
Mar 31, 2025
Armistice Capital LLC
291.15K
3.08%
+141.15K
+94.10%
Sep 30, 2024
Matejka & Partner Asset Management GmbH
63.80K
0.68%
--
--
Nov 30, 2024
Deutsche Balaton Aktiengesellschaft
58.88K
0.62%
+58.88K
--
Dec 20, 2024
Geode Capital Management, L.L.C.
40.14K
0.42%
+20.84K
+107.96%
Mar 31, 2025
Ver más
ETFs relacionados
Nombre
Proporción
Sin datos
Dividendos
Un total de
0.00
USD se ha distribuido en dividendos durante los últimos 5 años.
Fecha
Dividendos
Fecha de registro
Fecha de pago
Fecha ex-dividendo
Sin datos
División de acciones
Fecha
Tipo
Relación
Jul 03, 2023
Merger
20<1
Jul 03, 2023
Merger
20<1
Jul 03, 2023
Merger
20<1
Jul 03, 2023
Merger
20<1
Fecha
Tipo
Relación
Jul 03, 2023
Merger
20<1
Jul 03, 2023
Merger
20<1
Jul 03, 2023
Merger
20<1
Jul 03, 2023
Merger
20<1
